Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
M.D. Anderson Cancer Center
Primary Objectives
-To estimate the accuracy of F18 Fluciclovine PET MR for laser interstitial thermal therapy (LITT) treatment response assessment as determined by T1 post-contrast MR brain imaging.
Secondary Objectives
* To assess changes in F18 Fluciclovine defined disease with LITT.
* To assess the volume change of the idealized quantitative T1 values of lesions compared -To assess the volume change of idealized quantitative T2 values of lesions compared to -Chemical Exchange Saturation Transfer (CEST) MRI - To assess the ability of CEST imaging to differentiate treatment change from residual disease in brain malignancy following LITT.
* Multiple B Value Diffusion Imaging (Adv Diff) - To assess whether Adv Diff can differentiate treatment changes from residual disease in brain malignancy following LITT.
* Gradient- and Spin-Echo DSC perfusion imaging - To assess whether GESE DSC improves differentiation of treatment change from residual disease in brain malignancy -Adv ASL perfusion imaging - To assess the ability of Adv ASL to differentiate treatment change from residual disease in brain malignancy following radiation therapy.
* Exploratory Objectives
* To assess the relationship between post-LITT enhancing brain tissue and F18 -To assess changes in regional homogeneity (ReHo) values after LITT.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
An adult patient with suspected or pathology-proven central nervous system neoplasm.
MRI of the brain, positive for at least one intra-axial lesion greater than 5 mm.
You may not be if
Contraindication to MR imaging.
Known allergy to gadolinium-based contrast agents.
Renal failure as defined by a GFR less than 30 or the use of hemodialysis.
Pregnant.
Patients less than 18 years of age will be excluded.
